Skip to content
  1. Home
  2. Peptide bioregulators
  3. Bronchogen

Peptide bioregulators

Bronchogen

Organ-targeted bioregulator from the Khavinson lineage, aimed at bronchial and respiratory tissue.

Approved in Russia Peptide bioregulators Recovery & healing

Reviewed 2026-09-12
Full name
Bronchogen (Ala-Glu-Asp-Leu)
Also known as
AEDL peptide
Regulatory status
Approved in Russia

Origin

Developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology from amino-acid analysis of bronchial and respiratory tissue extracts; part of the Russian tissue-specific bioregulator program dating to the 1980s.

Mechanism

Proposed to stimulate differentiation factors like CXCL12 and Hoxa3 in bronchial epithelial cells, especially in aging cultures, supporting lung tissue homeostasis.

Research summary

Evidence

Research is limited and comes almost entirely from Khavinson's group. A 2012 study showed tissue-specific stimulation of differentiation markers in human bronchial epithelial cells in vitro; older work showed stimulatory effects in organotypic lung culture. No human trials or large-cohort data exist in English-language literature. Evidence is small-sample, Russian-led, and unreplicated in the West.

Evidence tier: Approved in Russia — see the methodology note for how this is assessed.

Citations

Reported benefits

  • support for respiratory tissue structure
  • enhancement of bronchial epithelial cell renewal (preclinical)
  • potential immunoprotective effects on lung tissue

Dosing protocols reported in the literature & community

These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.

Reported dosing protocols
RouteReported protocol
Intramuscular injection or oral tabletRussian clinical use reports vary; community sourcing reports 10-20 mg subcutaneously, unstandardized in Western literature.

Side effects

  • minimal reported; low toxicity profile typical of short peptide preparations

Safety notes

Safety: No serious adverse effects reported in Russian studies. Sterility and purity of imported or self-compounded preparations can't be guaranteed, and long-term human safety is undocumented.
Community & reddit notes (anecdotal — not clinical evidence)

Sourced by Western biohackers from Russian compounding services as part of the broader Khavinson suite; use is anecdotal with no systematic monitoring.